Advisory Research Inc. held its position in shares of bluebird bio, Inc. (NASDAQ:BLUE) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 28,050 shares of the biotechnology company’s stock at the end of the 2nd quarter. Advisory Research Inc. owned about 0.06% of bluebird bio worth $2,550,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also bought and sold shares of BLUE. BlackRock Inc. grew its position in bluebird bio by 44,948.0% in the first quarter. BlackRock Inc. now owns 3,182,188 shares of the biotechnology company’s stock worth $289,259,000 after acquiring an additional 3,175,124 shares in the last quarter. FMR LLC grew its position in bluebird bio by 9.6% in the second quarter. FMR LLC now owns 6,713,949 shares of the biotechnology company’s stock worth $705,301,000 after acquiring an additional 587,236 shares in the last quarter. Capital Research Global Investors grew its position in bluebird bio by 9.9% in the second quarter. Capital Research Global Investors now owns 5,483,117 shares of the biotechnology company’s stock worth $576,001,000 after acquiring an additional 493,072 shares in the last quarter. Vanguard Group Inc. grew its position in bluebird bio by 10.7% in the second quarter. Vanguard Group Inc. now owns 3,559,102 shares of the biotechnology company’s stock worth $373,884,000 after acquiring an additional 343,856 shares in the last quarter. Finally, Voya Investment Management LLC grew its position in bluebird bio by 1,251.6% in the second quarter. Voya Investment Management LLC now owns 217,398 shares of the biotechnology company’s stock worth $22,837,000 after acquiring an additional 201,313 shares in the last quarter.

In other bluebird bio news, insider Eric Sullivan sold 861 shares of bluebird bio stock in a transaction on Friday, August 4th. The shares were sold at an average price of $93.83, for a total transaction of $80,787.63. Following the completion of the transaction, the insider now directly owns 5,924 shares of the company’s stock, valued at $555,848.92. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider David Davidson sold 4,000 shares of bluebird bio stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $131.31, for a total transaction of $525,240.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 126,879 shares of company stock valued at $15,401,808. Company insiders own 3.90% of the company’s stock.

Shares of bluebird bio, Inc. (BLUE) traded down 1.48% during mid-day trading on Wednesday, reaching $129.70. 51,713 shares of the company’s stock were exchanged. The stock’s market cap is $5.91 billion. bluebird bio, Inc. has a 52-week low of $37.05 and a 52-week high of $143.50. The stock’s 50-day moving average is $123.70 and its 200-day moving average is $101.61.

bluebird bio (NASDAQ:BLUE) last released its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.73) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.66) by ($0.07). bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. The company had revenue of $16.70 million for the quarter, compared to the consensus estimate of $6.29 million. During the same period last year, the firm earned ($1.59) earnings per share. The company’s revenue for the quarter was up 977.4% compared to the same quarter last year. On average, equities analysts expect that bluebird bio, Inc. will post ($6.85) EPS for the current year.

Several analysts recently issued reports on BLUE shares. Zacks Investment Research downgraded shares of bluebird bio from a “buy” rating to a “hold” rating in a report on Tuesday, July 18th. BidaskClub downgraded shares of bluebird bio from a “hold” rating to a “sell” rating in a report on Wednesday, August 2nd. Jefferies Group LLC reaffirmed a “buy” rating and set a $88.00 price objective on shares of bluebird bio in a report on Friday, August 11th. Morgan Stanley downgraded shares of bluebird bio from an “equal weight” rating to an “underweight” rating and set a $105.00 price objective for the company. in a report on Monday, October 2nd. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and set a $186.00 price objective on shares of bluebird bio in a report on Friday, October 6th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $116.91.

WARNING: “Advisory Research Inc. Continues to Hold Position in bluebird bio, Inc. (BLUE)” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another site, it was stolen and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/10/11/advisory-research-inc-continues-to-hold-position-in-bluebird-bio-inc-blue.html.

About bluebird bio

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio, Inc. (NASDAQ:BLUE).

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Stock Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related stocks with our FREE daily email newsletter.